38373-55-6

Basic information

• Product Name: 2-Benzylamino-5-bromopyrimidine
• Synonyms: 2-Benzylamino-5-bromopyrimidine
• CAS NO: 38373-55-6
• Molecular Formula: C₁₁H₁₀BrN₃
• Molecular Weight: 264.1212
• Mol File: 38373-55-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Benzylamino-5-bromopyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Benzylamino-5-bromopyrimidine(38373-55-6)
• EPA Substance Registry System: 2-Benzylamino-5-bromopyrimidine(38373-55-6)

Safety Data

• Hazardous Substances Data: 38373-55-6(Hazardous Substances Data)

Usage

General Description

2-Benzylamino-5-bromopyrimidine is a chemical compound with the molecular formula C11H10BrN3. It is a pyrimidine derivative that contains a benzylamino group and a bromine atom. 2-Benzylamino-5-bromopyrimidine is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It is known for its potential biological activities and is being researched for its potential use as an anti-cancer agent. 2-Benzylamino-5-bromopyrimidine is a versatile chemical with a wide range of applications in the field of medicinal and agricultural chemistry.

Upstream product

• 7752-82-1 5-bromo-2-aminopyrimidine 
• 100-52-7 benzaldehyde 
• 4214-59-9 2-(benzylamino)pyrimidine 
• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 100-46-9 benzylamine 
• 62802-38-4 5-fluoro-2-(trifluoromethyl)pyrimidine 

Downstream Products

• 779329-82-7 N-(5-bromo-2-pyrimidinyl)-N-(phenylmethyl)-methansulfonamide 
• 1241897-98-2 2-(benzylamino)pyrimidine-5-carbonitrile 
• 1246749-79-0 N-benzyl-5-(2H-tetrazol-5-yl)pyrimidin-2-amine 
• 1241898-00-9 ethyl {5-[2-(benzylamino)pyrimidin-5-yl]-2H-tetrazol-2-yl}acetate 
• 1218789-30-0 C₁₇H₂₂BN₃O₂ 

Relevant articles and documents

Microwave-assisted synthesis of aminopyrimidines

Series of mono- or di-substituted aminopyrimidine derivatives were synthesized through microwave-assisted aromatic nucleophilic substitution or Suzuki coupling.

Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl) benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine315←isoleucine315 mutant

A series of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives were designed and synthesized as new Bcr-Abl inhibitors by using combinational strategies of bioisosteric replacement, scaffold hopping, and conformational constraint. The compounds displayed significant inhibition against a broad spectrum of Bcr-Abl mutants including the gatekeeper T315I and p-loop mutations, which are associated with disease progression in CML. The most potent compounds 6q and 6qo strongly inhibited the kinase activities of Bcr-AblWT and Bcr-AblT315I with IC50 values of 0.60, 0.36 and 1.12, 0.98 nM, respectively. They also potently suppressed the proliferation of K562, KU812 human CML cells, and a panel of murine Ba/F3 cells ectopically expressing either Bcr-AblWT or any of a panel of other Bcr-Abl mutants that have been shown to contribute to clinical acquired resistance, including Bcr-AblT315I, with IC50 values in low nanomolar ranges. These compounds may serve as lead compounds for further development of new Bcr-Abl inhibitors capable of overcoming clinical acquired resistance against imatinib.

HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, C═CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.